What is a dietary supplement?
Advances in technology and new ingredient discoveries have prompted the Food and Drug Administration (FDA) to rethink what constitutes a supplement. During a recent public meeting with industry representatives titled “Exploring the Scope of Dietary Supplement Ingredients,” the FDA tried to better define what makes up a dietary supplement.
The answer and its implications for consumers were an important topic of discussion. At its core, the conversation could reshape what qualifies as a dietary supplement and, ultimately, what products remain available to you.
Here are three key takeaways every consumer should understand:
“Dietary supplement” definition is under revieW
A central focus of the meeting was how to interpret the phrase “dietary substance…to supplement the diet,” as outlined in the Dietary Supplement Health and Education Act (DSHEA).
As new ingredients emerge, regulators are questioning whether substances which were not originally part of the human diet should still qualify. This debate could narrow — or expand — the types of ingredients allowed in supplements, directly impacting product availability.
New technologies are changing the supplement landscape
Advancements like precision fermentation, cell culture, and recombinant processes are enabling the creation of novel ingredients. The FDA is now evaluating whether these lab-derived or highly engineered compounds fit within existing supplement definitions. If not, some products currently on the market could face new regulatory hurdles — or even removal.
What counts as an ingredient is getting more complex
The agency is also examining how to classify ingredients such as proteins, enzymes, and microorganisms, which are not clearly defined in current law. Determining whether similar substances are considered the “same” ingredient could influence how products are regulated, labeled, and approved — potentially affecting both innovation and consumer choice.
|
Comparison of Stakeholder Positions
|
||
|
Stakeholder
|
Position
|
Supporting Evidence
|
| Industry (e.g., Natural Products Association) | Push to broaden DSHEA definitions to include peptides, novel probiotics, and other non-traditional substances. Argue FDA rules are outdated and stifle innovation. | Industry requested the meeting; cited regulatory uncertainty and cost. |
| FDA Leadership | Open to modernizing framework but focused on safety, identity, and production/method impacts. | FDA emphasized understanding how new technologies affect ingredient identity and safety. |
| Consumer Advocates | Concerned about safety of untested novel ingredients and lack of clarity around identity and composition. | Reflected in FDA’s questions about identity, safety, and production changes. |
| Academics/Scientists | Highlight need for clearer criteria for proteins, enzymes, microbials, and for evaluating technological modifications. | |
Why this should matter to you
These discussions could redefine access to supplements. A narrower interpretation of dietary supplements may limit options, increase costs, or delay innovation. A broader interpretation could preserve access but raise new questions about federal oversight and consumer safety.
Your voice matters
The FDA is actively seeking public input before making decisions, with comments accepted through April 27, 2026. Now is the time to stay informed, speak up, and ensure consumer access and choice remain part of the conversation.
(Written by Citizens for Health with supporting research assistance from AI.)
